ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Purchased by Wells Fargo & Company MN

Wells Fargo & Company MN raised its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 35.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 10,169 shares of the specialty pharmaceutical company’s stock after buying an additional 2,676 shares during the period. Wells Fargo & Company MN’s holdings in ANI Pharmaceuticals were worth $562,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. US Bancorp DE boosted its stake in ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after purchasing an additional 531 shares during the last quarter. KBC Group NV lifted its stake in shares of ANI Pharmaceuticals by 89.2% in the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after buying an additional 600 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in ANI Pharmaceuticals in the 4th quarter valued at about $166,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of ANI Pharmaceuticals by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock worth $246,000 after purchasing an additional 412 shares during the last quarter. Finally, Integrated Quantitative Investments LLC acquired a new stake in shares of ANI Pharmaceuticals in the fourth quarter valued at approximately $271,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Up 3.2 %

Shares of NASDAQ:ANIP opened at $72.95 on Friday. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The firm has a market capitalization of $1.59 billion, a PE ratio of -132.64 and a beta of 0.49. The firm’s 50-day moving average is $65.61 and its two-hundred day moving average is $60.32. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $73.16.

Analyst Ratings Changes

Several analysts have issued reports on ANIP shares. JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 target price for the company. StockNews.com lowered shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, April 24th. Truist Financial lifted their price target on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a research report on Monday, April 21st. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a “buy” rating and a $80.00 price objective for the company. Finally, Guggenheim restated a “buy” rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $80.13.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $68.96, for a total value of $27,584.00. Following the sale, the vice president now owns 80,145 shares of the company’s stock, valued at $5,526,799.20. This trade represents a 0.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the completion of the transaction, the senior vice president now owns 66,525 shares of the company’s stock, valued at $4,048,711.50. The trade was a 1.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,200 shares of company stock worth $197,792 in the last ninety days. 11.10% of the stock is owned by corporate insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.